19 de mayo de 2019
  • Sábado, 18 de Mayo
  • Viernes, 17 de Mayo
  • 16 de septiembre de 2008

    New Data Confirms Avastin (R) as the Only Biologic to Demonstrate Overall Survival When Used First-Line in Metastatic Co


    - There was no statistical difference in overall survival (OS)
    in the K-Ras wild-type population - the study was negative for this
    secondary endpoint (24.9 vs. 21.0 months in the cetuximab and control
    arm respectively) (HR 0.84, p 0.22)
    - There was no statistical difference in OS in the general
    study population - the study therefore failed to meet this key
    secondary endpoint (19.9 vs. 18.6 months in the cetuximab and control
    arm respectively) (HR 0.93, p 0.30)

    Main outcomes from pivotal Avastin 2107 study which demonstrated Avastin's superior K-Ras data:

    [TAB]

    - Avastin provides a statistically significant OS advantage in

    the K-Ras wild-type population (27.7 vs. 17.6 months in the Avastin and

    Control arm respectively) (HR 0.58, p 0.04)

    - Avastin also provides statistically significant improvements

    in the time patients live without their disease worsening for both K-

    Ras wild-type (PFS improved by 82%, from 7.4 to 13.5 months, hazard

    ratio: 0.44, p<0.0001) and K-Ras mutant patients (PFS improved by 69%,

    from 5.5 to 9.4 months, hazard ratio: 0.41, p=0.0008).

    - Avastin provides a statistically significant gain in OS in

    the general population (20.3 vs. 15.6 months in the Avastin and control

    arm respectively) (HR 0.66, p<0.001)

    - The overall survival benefit of Avastin has been confirmed

    in two large community-based studies (First BEAT / BRiTE), including

    some 4,000 patients

    [FTAB]

    In January 2008, Avastin received a broad label in the EU allowing it to be used in combination with fluoropyrimidine-based chemotherapy for first and later treatment lines in patients with mCRC. This means that virtually all patients with metastatic colorectal cancer have access to Avastin's benefits.

    Additional information

    [TAB]

    http://www.avastin-info.com

    http://www.Roche.com

    http://www.thenewsmarket.com (video clips about Avastin in broadcast

    standard, free of charge)

    [FTAB]

    For more information please contact, Galliard Healthcare, Dominic Elliston, +44-20-7663-2266, delliston@galliardhealth.com


    http://www.avastin-info.com
    http://www.Roche.com
    http://www.thenewsmarket.com (video clips about Avastin in broadcast
    standard, free of charge)

    For more information please contact, Galliard Healthcare, Dominic Elliston, +44-20-7663-2266, delliston@galliardhealth.com